Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent and MD Anderson Partner to Test Tyvyt® in Rare Cancers

publication date: May 19, 2020

Innovent, a Suzhou biotech, announced a strategic collaboration with the MD Anderson Cancer Center of Houston to conduct US trials of its approved anti-PD-1 checkpoint inhibitor, Tyvyt® in patients with very rare cancers. Innovent and MD Anderson will co-fund the trials, which will be conducted by MD Anderson. Upon commercialization for the rare forms of cancer, Innovent will make royalty payments to MD Anderson, which will use the proceeds to fund care for uninsured patients. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.